144 - May 28, 2025 | SEC Filings

Brief

Form 144 discloses Rocket Lab officer Frank Klein's proposed sale of 2,569 common shares, acquired via RSUs on March 1, 2025, with market value $73,884. Sale relies on 10b5-1 plan adopted December 13, 2024; recent March sales totaled 46,388 shares for $846,603. Routine insider liquidity with minimal investor relevance amid 461M shares outstanding.

Detailed Brief

Rocket Lab USA, Inc. officer Frank Klein filed Form 144 on May 28, 2025, notifying intent to sell 2,569 common shares through Morgan Stanley, approximate date May 28, 2025. Shares stem from restricted stock unit vesting on March 1, 2025, directly from issuer. The transaction follows a Rule 10b5-1 trading plan adopted December 13, 2024, ensuring pre-planned sales without insider knowledge. Klein reports no undisclosed material adverse information. In the past three months, Klein sold 44,553 shares on March 14 ($810,031) and 1,835 on March 17 ($36,572), likely tied to compensation vesting in Rocket Lab's launch services business. Total recent volume is negligible against 461,432,393 shares outstanding, representing standard executive liquidity.

Key Telemetry

• Officer Frank Klein to sell 2,569 common shares (~$73,884) on 5/28/2025.

• Shares from 3/1/2025 RSU vesting; under 10b5-1 plan (adopted 12/13/2024).

• Past 3 months: Sold 46,388 shares total ($846,603) on 3/14 & 3/17.

• 461M shares outstanding; no material adverse info disclosed.

• Broker: Morgan Stanley Smith Barney LLC.

Impact Vector

Negligible near-term impact on Rocket Lab stock as sale is tiny (0.0006% of shares outstanding) and pre-planned under 10b5-1, signaling routine RSU monetization rather than distress. No strategic shift; common for executives in growth firms like space launch. Monitor for sales clusters or volume spikes, but isolated low-volume event unlikely to signal issues amid company's operational focus.